Renal function following liver transplantation for unresectable hepatoblastoma

Pediatric Transplantation

Volumn 7, Issue 4, 2003, Pages 270-276

  Lee, Way Seah ^a   Grundy, R ^b   Milford, D V ^b   Taylor, C M ^b   De Ville de Goyet, J ^b   McKiernan, P J ^b   Beath, S V ^b   Kelly, D A ^b  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Hepatoblastoma; Liver transplantation; Renal function

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DOXORUBICIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HEPATOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD;

EID: 0041734791     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00040.x     Document Type: Article

References (32)

1. NINANE J, PERILONGO G, STALENS JP, GUGLIELMI M, OTEE JB, MANCINI A. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study. Med Pediatr Oncol 1991: 19: 199-203.
2. PRITCHARD J, BROWN J, SHAFFORD E, PERILONGO G, BROCK P, DICKS-MIREAUX C, et al. Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000: 18: 3819-3828.
3. BILIK R, SUPERINA R. Transplantation for unresectable liver tumors in children. Transplantat Proc 1997: 29: 2834-2835.
4. AL-QABANDI W, JENKINSON HC, BUCKELS JA, MAYER AD, McKIERNAN PJ, MORLAND B, et al. Orthotopic liver transplantation for unresectable hepatoblastoma: a single center's experience. J Pediatr Surg 1999: 34: 1261-1264.
5. DOWER NA, SMITH LJ, LEES G, KNETEMAN N, EDMOND J, et al. Experience with aggressive therapy in three children with unresectable malignant liver tumors. Med Ped Oncol 2000: 34: 132-135.
6. REYES JD, CARR B, DVORCHIK I, KOCOSHIS S, JAFFE R, GERBER D, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 2000: 136: 795-804.
7. MOLMENTI EP, NAGATA D, RODEN J, SQUIRES R, MOLMENTI H, CASEY D, et al. Liver transplantation for hepatoblastoma in the pediatric population. Transplant Proc 2001: 33: 1749.
8. WOMER RB, PRITCHARD J, BARRATT TM. Renal toxicity of cisplatin in children. J Pediatr 1985: 106: 659-663.
9. BROCK PR, KOLIOUSKAS DE, BARRATT TM, YEOMANS E, PRITCHARD J. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991: 118: 531-534.
10. ENGLISH MW, SKINNER R, PEARSON AD, PRICE L, WYLIE R, CRAFT AW. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999: 81: 336-41.
11. LAFAYETTE RA, PARE G, SCHMID CH, KING AJ, ROHRER RJ, NASRAWAY SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997: 48: 159-164.
12. GONWA TA, KLINTMALM GB, LEVY M, JENNINGS LS, GOLDSTEIN RM, HUSSERG BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995: 59: 361-365.
13. , McDIARMID SV, COLONNA JO, SHAKED A, AMENT ME, BUSUTTIL RW, A comparison of renal function in cyclosporin and FK506 treated patients after primary orthotopic liver transplantation. Transplantation 1993: 56: 847-853.
14. PORAYKO MK, TEXTOR SC, KROM RAF, HAY JE, GORES GJ, RICHARDS TM, et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporin regimens after liver transplantation. Mayo Clinic Proc 1994: 69: 105-111.
15. SCHWARTZ GJ, HAYCOCK GB, EDELMANN CM, SPITZER A. A simple estimate of glomerular filtration rate in children from body length and plasma creatinine. Pediatr 1976: 58: 259-263.
16. SCHWARTZ GJ, GAUTHIER B. A simple estimate glomerular filtration rate in adolescent boys. J Pediatr 1985: 106: 522-526.
17. DAVIES JG, TAYLOR CM, WHITE RHR, MARSHALL T. Clinical limitations of the estimation of glomerular filtration rate from height/plasma creatinine: a comparison with simultaneous 51-Cr edetic acid slope clearance. Arch Dis Child 1982: 57: 507-510.
18. ANDRE JL, DESCHAMPS JP, GUEGUEN R. Arterial blood pressure in 17067 children and adolescents. Variation with age and height. Arch Fr Pediatr 1980: 37: 477-482.
19. LOKICH J, ANDERSON N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998: 9: 13-21.
20. REMUZZI G, PERICO N. Cyclosporin-induced renal dysfunction in experimental animals and humans. Kidney Int 1995: 48: S70-S74.
21. ENGLISH J, EVANS A, HOUGHTON DC, BENNETT WM. Cyclosporin-induced acute renal dysfunction in the rat: Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987: 44: 135-141.
22. McDIARMID SV, ETTENGER RB, FINE RN, BUSUTTIL RW, AMENT ME. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporin. Transplantation 1989: 47: 314-318.
23. MOR E, PATEL T, GLABMAN S, SHEINER P, EMRE S, GUY S, et al. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK506. Transplant International 1994: 7(Suppl 1), S77-S80.
24. McCAULEY J. The nephrotoxicity of FK506 as compared with cyclosporin. Curr Opin Nephrol Hypertens 1993: 2: 662-669.
25. ARORA N, BUNN S, McKIERNAN PJ, BEATH SV, DE VILLE DE GOYET J, KELLY DA. Long-term evaluation of renal function after paediatric liver transplantation. Hepatology 2000: 32: 341A.
26. MIHATSCH MJ, RYFFEL B, GUDAT F, et al. The differential diagnosis between rejection and cyclosporin toxicity. Kidney Int 1995: 48: S63-S69.
27. The US Multicentre FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Eng J Med 1994: 331: 1110-1115.
28. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994: 344: 423-428.
29. SCHLITT HJ, BARKMANN A, BOKER KH, SCHMITT HH, EMMANOUILIDIS N, ROSENAU J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001: 357: 587-591
30. DIVID-NETO E, ARANJO LM, LEMOS FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001: 5: 302-309.
31. BARKMANN A, NASHAN B, SCHMIDT HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000: 69: 1886-1890.
32. SEIKALY MG, BROWNE R, BAJAJ G, ARANT BS JR. Limitations to body length/serum creatinine ratio as an estimate of glomerular filtration in children. Pediatr Nephrol 1996: 10: 709-711.